CVS Caremark is adding Zepbound, Eli Lilly’s obesity drug, back to its commercial insurance plan formularies, more than a ...

More than 10 million US patients will regain easy access to Eli Lilly & Co.’s obesity shot Zepbound through insurance after ...

CVS Health (NYSE: CVS) today announced updates to its most common commercial formularies, expanding GLP-1 options for members— including the reintroduction of Zepbound® (tirzepatide) as a covered ...

CVS Caremark, one of the three major pharmacy benefit managers (PBM) in the U.S., stopped coverage for Eli Lilly's popular weight-loss drug Zepbound, blaming drugs like it for driving up overall plan ...